Entry into a Material Definitive Agreement

Business Context and Reporting Period

Company: Ekso Bionics Holdings, Inc. (Note: Input metadata referenced "Chronoscale Corp," but the filing text identifies Ekso Bionics Holdings, Inc.)
Filing Type: Form 8-K (Current Report)
Date: March 17, 2025
Context: The Company entered into a warrant inducement agreement with an existing holder of Series A and Series B Warrants to facilitate the cash exercise of existing warrants in exchange for new inducement warrants.

Key Financial Metrics and Transaction Details

  • Existing Warrant Exercise: Investor agreed to exercise warrants for 9,800,000 shares of Common Stock.
  • Exercise Price: Reduced to $0.4239 per share for both existing and new warrants.
  • New Inducement Warrant: Issued for up to 10,500,000 shares of Common Stock.
  • Inducement Warrant Terms:
    • Exercise Price: $0.4239 per share.
    • Term: 5 years from the Stockholder Approval Date.
    • Exercisability: Commences upon stockholder approval.
  • Beneficial Ownership Limitation: 4.99% of outstanding shares (electable up to 9.99% with 61 days' notice).

Material Changes and Covenants

The filing details a material modification to the rights of security holders and the entry into a definitive agreement. Key changes and restrictions include:

  • Stockholder Approval Requirement: The Company must seek stockholder approval for the Inducement Warrant at an annual or special meeting held on or prior to July 15, 2025.
  • Issuance Restrictions:
    • No issuance of Common Stock or equivalents until May 31, 2025 (subject to exceptions).
    • No Variable Rate Transactions until September 13, 2025.
  • Registration Obligation: The Company must file a registration statement (Form S-3 or S-1) within 30 days of the Stockholder Approval Date for the resale of Inducement Warrant Shares.
  • Abeyance Provision: If exercising existing warrants would exceed the 4.99% beneficial ownership limit, shares are held in abeyance until the investor directs issuance in compliance with the limit.

Guidance, Outlook, and Risks

Management Commentary: The filing does not contain forward-looking financial guidance, revenue outlook, or general management commentary beyond the specific terms of the warrant agreement.

Risks and Contingencies:

  • Dilution Risk: The transaction involves the potential issuance of up to 10,500,000 new shares via the Inducement Warrant, subject to stockholder approval.
  • Approval Contingency: The exercisability of the new warrants is contingent upon obtaining stockholder approval by July 15, 2025.
  • Liquidity Impact: While the agreement secures cash from the exercise of existing warrants, the filing does not quantify the total cash proceeds or current liquidity position.

Investor Verification Checklist

  • Verify the total cash proceeds received from the exercise of the 9,800,000 existing warrants at $0.4239 per share.
  • Confirm the date and outcome of the stockholder meeting required to approve the Inducement Warrant (deadline: July 15, 2025).
  • Review the full text of the Inducement Agreement (Exhibit 10.1) for specific exceptions to the issuance blackout periods.
  • Monitor the filing of the resale registration statement (Form S-3 or S-1) within 30 days of stockholder approval.
  • Assess the impact of the 10,500,000 inducement shares on fully diluted share count and earnings per share.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.